drugset / Trial / NCT07644247
STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump
Phase 4
Not yet recruiting
370 enrolled
China National Center for Cardiovascular Diseases
Beijing Anzhen Hospital · collabChinese Academy of Medical Sciences, Fuwai Hospital · collabFirst Affiliated Hospital Xi'an Jiaotong University · collabFirst Affiliated Hospital of Xinjiang Medical University · collabFujian Provincial Hospital · collabFuwai Yunnan Cardiovascular Hospital · collabGuangdong Provincial People's Hospital · collabHenan Provincial Chest Hospital · collabJiangsu Provincial People's Hospital · collabNanjing First Hospital, Nanjing Medical University · collabPeople's Hospital of Xinjiang Uygur Autonomous Region · collabRuijin Hospital · collabSecond Hospital of Jilin University · collabShanghai Zhongshan Hospital · collabSichuan Provincial People's Hospital · collabSir Run Run Shaw Hospital · collabThe 7th People's Hospital of Zhengzhou · collabUnion hospital of Fujian Medical University · collabWuhan Asia Heart Hospital · collabXijing Hospital · collabZhejiang Provincial People's Hospital · collabZhejiang University · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This multi-center, prospective, randomized, double-blinded, placebo-controlled study aims to investigate whether withdrawal of aspirin from the antithrombotic regimen in patients supported with the CH-VAD pump is non-inferior to the standard antithrombotic regimen of vitamin K antagonist combined with aspirin in terms of safety and efficacy.
Timeline
- Start
- 2026-06-25
- Primary completion
- 2029-01-01
- Completion
- 2029-12-31